The National Heart, Lung, and Blood Institute offers the SBIR Phase IIB Small Market Award to support Phase II SBIR awardees working on technologies for rare diseases or young pediatric populations. The grant aims to de-risk these technologies for continued development with private funding. Applicants must provide a Commercialization Plan detailing secured or anticipated independent third-party funding. Projects must require Federal regulatory approval and may involve preclinical and/or clinical stages, with clinical trials optional. The deadline for applications is June 19, 2015.
General Information
| Document Type:: |
Grants Notice |
| Funding Opportunity Number:: |
RFA-HL-14-012 |
| Funding Opportunity Title:: |
Small Market Awards: SBIR Phase IIB Competing Renewals for Heart, Lung, Blood and Sleep Technologies with Small Commercial Markets (R44) |
| Opportunity Category:: |
Discretionary |
| Opportunity Category Explanation:: |
|
| Funding Instrument Type:: |
|
| Category of Funding Activity:: |
Health |
| Category Explanation:: |
|
| Expected Number of Awards:: |
|
| Assistance Listings Number(s):: |
93.233 — National Center on Sleep Disorders Research |
| Cost Sharing or Matching Requirement:: |
No |
| Version:: |
Synopsis 2 |
| Posted Date:: |
Apr 16, 2013 |
| Last Updated Date:: |
Apr 16, 2013 |
| Original Closing Date for Applications:: |
Jun 19, 2015 |
| Current Closing Date for Applications:: |
Jun 19, 2015 |
| Archive Date:: |
Jul 20, 2015 |
| Estimated Total Program Funding:: |
$ 2,000,000 |
| Award Ceiling:: |
$ |
| Award Floor:: |
$ |
Eligibility
| Eligible Applicants:: |
Small businesses |
| Additional Information on Eligibility:: |
|
Additional Information
| Agency Name:: |
National Institutes of Health |
| Description:: |
The purpose of the NHLBI SBIR Phase IIB Small Market Award is to provide support to Phase II SBIR awardees developing NHLBI mission-related technologies that address a rare disease or young pediatric populations. The goal of this FOA is to de-risk these technologies so that development can continue with private funding after NHLBI support ends; therefore, applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will be equal to or greater than one-third of the NHLBI funds being requested throughout the project period. Projects proposed in response to this FOA must require eventual Federal regulatory approval/clearance, and may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required. |
| Link to Additional Information:: |
|
| Grantor Contact Information:: |
If you have difficulty accessing the full announcement electronically, please contact: |
Version History
| Version |
Modification Description |
Updated Date |
| Synopsis 2 |
Added CFDA number 93.350, per NCATS participation. |
Apr 16, 2013 |
| Synopsis 1 |
|
|
Related Documents
There are no related documents on this grant.
Packages
| Assistance Listings |
Competition ID |
Competition Title |
Opportunity Package ID |
Opening Date |
Closing Date |
Actions |
Who Can Apply: |
|
ADOBE-FORMS-B2 |
Adobe-Forms-B2 |
PKG00173951 |
May 19, 2013 |
Sep 07, 2014 |
View |
eRA Commons Help Desk
|
Organization Applicants |
| Assistance Listings |
Competition ID |
Competition Title |
Opportunity Package ID |
Opening Date |
Closing Date |
Actions |
Who Can Apply: |
|
FORMS-C |
FORMS-C |
PKG00204244 |
Aug 25, 2014 |
Jun 19, 2015 |
View |
eRA Commons Help Desk
|
Organization Applicants |
